HEALTHSTORY 533· AUGUST 4, 2026

Seven months after launch, Aurora Therapeutics scraps its lead gene-editing program and cuts staff

Personalized CRISPR therapies, gene-editing treatments built around one patient's specific mutation rather than a disease shared by millions, just lost one of their early backers. Aurora Therapeutics has scrapped its lead program and laid…

NDNewsDialy Desk2 MIN READ

SOURCE

statnews.com

← PREVIOUS STORY 532Columbus Acquisition Corp issues $50,000 in extension notes as SPAC merger deadline approaches NEXT STORY 534 →New Mountain Finance declares a $0.25 third-quarter dividend, expecting earnings to cover the payout

Keep reading

More from the desk.

01HEALTH

AstraZeneca's breast cancer pill camizestrant fails first-line trial

A breast cancer drug failed its largest clinical test, a result that could limit how widely the medicine is prescribed. First-line therapy is the term for the initial drug doctors try after a patient's cancer advances, before other options…

health2 MIN

18HEALTH

Federal health officials give states a clearer tool for Medicaid work exemptions

States can now sort Medicaid recipients into health-severity tiers when deciding who is too ill to work or volunteer, under guidance released this week by the Centers for Medicare and Medicaid Services. Medical frailty, in plain terms, is…

health2 MIN

23HEALTH

Venkat Krishnamurthy named chief scientific officer of Alloy Therapeutics' genetic medicines division

The scientific leader of a genetic medicines division has changed. Genetic medicines, in plain terms, is the field of therapies that act on DNA or RNA to treat disease at its source. Alloy Therapeutics is the company gaining a new leader…

health1 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk